Skip to content

BCG-induced Epigenetic Modifications in the NEXT Generation

BCG-induced Epigenetic Modifications in the NEXT Generation

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05766345
Acronym
NEXT
Enrollment
36
Registered
2023-03-13
Start date
2023-10-02
Completion date
2024-10-31
Last updated
2024-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BCG Vaccine, Epigenetics, Trained Immunity

Brief summary

Non-specific protective effects resulting from the BCG vaccine appear to be paternally inheritable. Since the BCG vaccine is known to induce trained immunity, epigenetics might explain the fathers' contribution to the immune profile of their offspring. Epigenetic inheritance in mice has recently been demonstrated, but is not established in humans yet. By studying the DNA methylation profile of sperm cells after BCG vaccination, we aim to gain insight into the possibility of epigenetic inheritance in human males.

Interventions

BIOLOGICALBCG-Vaccine SSI [Statens Serum Institut]) Danish strain 1331

Nothing to add

BIOLOGICALPlacebo

Nothing to add

Sponsors

Radboud University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
18 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy * Male * Age 18-25 years (at the moment of trial start)

Exclusion criteria

* Any systemic disease or conditin, or the use of systemic medication (with the exception of non-threatening alelrgies, e.g. hay fever) * Smoking or drug use * Prior BCG vaccination * Other vaccination four weeks prior to trial start or four weeks after the first study visit (no vaccine in the same arm as the BCG vaccine for three months) * Acute illness two weeks prior to trial start * Known allergy or history of anaphylaxis/other serious adverse reaction to any vaccine * Participation in another drug trial * Legally incapacitated or unwilling to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
DNA methylation profile of sperm cells (first comparison; CHANGE)Comparing T3 to baselineDifferentially methylated regions (DMRs)
DNA methylation profile of sperm cells (second comparison; CHANGE)Comparing T4 to baselineDifferentially methylated regions (DMRs)

Secondary

MeasureTime frameDescription
Immunological profile of PBMCs, before and after BCG vaccination (comparison; CHANGE)Comparing T1-T4 to baselineCytokine production assays (e.g. TNFa, IL6, IL1b)
CHANGE of the epigenetic profile of innate immune cellsComparing T1-T4 to baselineDifferentially methylated regions (DMRs), ATAC sequencing, RNA sequencing

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026